Designing a Drug for COVID-19 and Other Respiratory Diseases

Delivering a therapeutic directly to the lungs is often the best route to treating diseased lung tissue but designing a drug for inhaled delivery is tricky. Medicinal chemistry in early discovery can be critical in shortening time to market, achieving maximum efficacy, and ensuring the safety of the inhaled drug.

Charles River offers medicinal chemistry, pharmaceutics, DMPK and In vivo pharmacology services to support inhaled drug and inhaled therapy with the greatest efficacy and safety for respiratory diseases.
Charles River offers webinar titled “Designing a Drug for COVID-19: Considerations for Inhaled Therapeutics to Treat Respiratory Diseases”

Webinar: Designing a Drug for COVID-19: Considerations for Inhaled Therapeutics to Treat Respiratory Diseases

The 2020 COVID-19 pandemic has brought into focus the devastating impact of lung diseases, with scientists around the world urgently seeking new therapies. Inhaled delivery of therapy can provide great advantages, including direct delivery to site of action, high local concentration in the lung and fast onset of action. If you’re considering an inhaled formulation, join us for valuable guidance on respiratory drug design.

Watch webinar


Charles River offers webinar titled “Physicochemical Profiling of Powders for Inhalation” to present how to determine physicochemical properties of powder test items can reduce aerosol generattion variability and lead to more consistence in doses administered.

Webinar: Physicochemical Profiling of Powders for Inhalation

Dry powders are the most common type of inhalation test item currently, but also some of the most problematic. In a powder, there are inter-particle forces between all the particles that determine how they will flow and ultimately aerosolize. This is critical to understand prior to the start of running an inhalation toxicology study. In this webinar, you will learn how determining physicochemical properties of powder test items can reduce aerosol generation variability and lead to more consistency in doses administered.

Watch webinar